Marcela V Maus1, Michail S Lionakis2. 1. Cellular Immunotherapy Program, Massachusetts General Hospital Cancer Center and Department of Medicine, Harvard Medical School, Boston, Massachusetts. 2. Fungal Pathogenesis Section, Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy & Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
Abstract
PURPOSE OF REVIEW: In recent years, we have witnessed a remarkable surge in the clinical development of effective biological and cellular therapies for the treatment of neoplastic and autoimmune disorders. The present review summarizes our understanding of the pathogen-specific infection risk associated with the use of such therapies. RECENT FINDINGS: A variety of biologics, in the form of either monoclonal antibodies (Mabs) or small molecule kinase inhibitors (Nibs), are continuously introduced in the clinic for the management of autoimmune and malignant diseases. In addition, cellular therapies such as the infusion of chimeric antigen receptor (CAR) T-cells are becoming increasingly available for patients with treatment-refractory lymphoid malignancies. Some of these biological and cellular interventions exert direct or indirect adverse effects on the induction of protective immune responses against various pathogens, resulting in heightened infection susceptibility. SUMMARY: The introduction of biological and cellular therapies for the treatment of malignant and autoimmune diseases has been associated with increased infection susceptiblity, which varies greatly depending on the specific immunomodulatory therapy, the infecting pathogen and the recipient patient population. A high index of clinical suspicion and efforts aiming at early diagnosis, targeted vaccination or prophylaxis, and prompt initiation of antimicrobial treatment should help improve infection outcomes.
PURPOSE OF REVIEW: In recent years, we have witnessed a remarkable surge in the clinical development of effective biological and cellular therapies for the treatment of neoplastic and autoimmune disorders. The present review summarizes our understanding of the pathogen-specific infection risk associated with the use of such therapies. RECENT FINDINGS: A variety of biologics, in the form of either monoclonal antibodies (Mabs) or small molecule kinase inhibitors (Nibs), are continuously introduced in the clinic for the management of autoimmune and malignant diseases. In addition, cellular therapies such as the infusion of chimeric antigen receptor (CAR) T-cells are becoming increasingly available for patients with treatment-refractory lymphoid malignancies. Some of these biological and cellular interventions exert direct or indirect adverse effects on the induction of protective immune responses against various pathogens, resulting in heightened infection susceptibility. SUMMARY: The introduction of biological and cellular therapies for the treatment of malignant and autoimmune diseases has been associated with increased infection susceptiblity, which varies greatly depending on the specific immunomodulatory therapy, the infecting pathogen and the recipient patient population. A high index of clinical suspicion and efforts aiming at early diagnosis, targeted vaccination or prophylaxis, and prompt initiation of antimicrobial treatment should help improve infection outcomes.
Authors: Paschalis Vergidis; Robin K Avery; L Joseph Wheat; Jennifer L Dotson; Maha A Assi; Smyrna A Antoun; Kassem A Hamoud; Steven D Burdette; Alison G Freifeld; David S McKinsey; Mary E Money; Thein Myint; David R Andes; Cynthia A Hoey; Daniel A Kaul; Jana K Dickter; David E Liebers; Rachel A Miller; William E Muth; Vidhya Prakash; Frederick T Steiner; Randall C Walker; Chadi A Hage Journal: Clin Infect Dis Date: 2015-04-13 Impact factor: 9.079
Authors: Christian Grommes; Alessandro Pastore; Nicolaos Palaskas; Sarah S Tang; Carl Campos; Derrek Schartz; Paolo Codega; Donna Nichol; Owen Clark; Wan-Ying Hsieh; Dan Rohle; Marc Rosenblum; Agnes Viale; Viviane S Tabar; Cameron W Brennan; Igor T Gavrilovic; Thomas J Kaley; Craig P Nolan; Antonio Omuro; Elena Pentsova; Alissa A Thomas; Elina Tsyvkin; Ariela Noy; M Lia Palomba; Paul Hamlin; Craig S Sauter; Craig H Moskowitz; Julia Wolfe; Ahmet Dogan; Minhee Won; Jon Glass; Scott Peak; Enrico C Lallana; Vaios Hatzoglou; Anne S Reiner; Philip H Gutin; Jason T Huse; Katherine S Panageas; Thomas G Graeber; Nikolaus Schultz; Lisa M DeAngelis; Ingo K Mellinghoff Journal: Cancer Discov Date: 2017-06-15 Impact factor: 39.397
Authors: A Moruno-Rodríguez; J L Sánchez-Vicente; T Rueda-Rueda; B Lechón-Caballero; A Muñoz-Morales; F López-Herrero Journal: Arch Soc Esp Oftalmol (Engl Ed) Date: 2019-01-31
Authors: Daniel L Barber; Shunsuke Sakai; Ragini R Kudchadkar; Steven P Fling; Tracey A Day; Julie A Vergara; David Ashkin; Jonathan H Cheng; Lisa M Lundgren; Vanessa N Raabe; Colleen S Kraft; Jorge J Nieva; Martin A Cheever; Paul T Nghiem; Elad Sharon Journal: Sci Transl Med Date: 2019-01-16 Impact factor: 17.956
Authors: Katie Bechman; Sujith Subesinghe; Sam Norton; Fabiola Atzeni; Massimo Galli; Andrew P Cope; Kevin L Winthrop; James B Galloway Journal: Rheumatology (Oxford) Date: 2019-10-01 Impact factor: 7.580
Authors: Frederick L Locke; Sattva S Neelapu; Nancy L Bartlett; Tanya Siddiqi; Julio C Chavez; Chitra M Hosing; Armin Ghobadi; Lihua E Budde; Adrian Bot; John M Rossi; Yizhou Jiang; Allen X Xue; Meg Elias; Jeff Aycock; Jeff Wiezorek; William Y Go Journal: Mol Ther Date: 2017-01-04 Impact factor: 11.454